Willem Oosterlinck

Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials

Richard Sylvester, Adrian P.M. van der Meijden, Willem Oosterlinck et al. · European Urology · 2006 · 3K citations

Medicine, Oncology, Urology +10

EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin

Samantha Cambier, Richard Sylvester, Laurence Collette et al. · European Urology · 2015 · 640 citations · Full text

Medicine, Oncology, Urology +12

European Guidelines for the Diagnosis and Management of Upper Urinary Tract Urothelial Cell Carcinomas: 2011 Update

Morgan Rouprêt, Richard Zigeuner, Juan Palou et al. · European Urology · 2011 · 398 citations

Medicine, Oncology, Urology +12

Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG

Maurizio Brausi, Jorg R. Oddens, Richard Sylvester et al. · European Urology · 2013 · 379 citations · Full text

Medicine, Oncology, Urology +9

A Prospective European Organization for Research and Treatment of Cancer Genitourinary Group Randomized Trial Comparing Transurethral Resection Followed by a Single Intravesical Instillation of Epirubicin or Water in Single Stage Ta, T1 Papillary Carcinoma of the Bladder

Willem Oosterlinck, Karl H. Kurth, Fritz H. Schröder et al. · The Journal of Urology · 1993 · 367 citations

Medicine, Surgery, Urology +12